This Week on NeuroScientistNews: 13 April – 17 April
News Apr 17, 2015
Anxiety and outcome prediction; fatty acids and brain development; DBS and Parkinson’s disease, and more.
Making decisions is a complex process that is made easier when the outcomes of actions are predictable. Researchers know that people with high anxiety are more likely to interpret unexpected variability as a sign of catastrophe. For example, a good student with low or average anxiety may receive a poor mark on an exam, and interpret this as a sign to study more or do better next time, while a good student with high anxiety might see this poor mark as a sign that they’ll fail the entire course. It is thought that anxious individuals have difficulty updating their expectations when outcomes become more variable, and that this difficulty may stem from an impaired ability to use environmental cues to help them learn to avoid a bad outcome.
A new study suggests that an investigational drug for multiple sclerosis (MS) may repair myelin according to a study that will be presented at the American Academy of Neurology’s 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
While recent reports question whether fish oil supplements support heart health, University of California, Irvine scientists have found that the fatty acids they contain are vitally important to the developing brain.
University of California San Francisco scientists have discovered a possible mechanism for how deep-brain stimulation (DBS), a widely used treatment for movement disorders, exerts its therapeutic effects.
Because the spine is made up of repeating elements that look alike, surgeons can mistakenly operate on the wrong vertebra. To avoid this, Johns Hopkins researchers have developed a software program that works seamlessly with currently available procedures to assist a surgeon's determination of which vertebra is which. Results from its first clinical evaluation show that the LevelCheck software achieves 100 percent accuracy in just 26 seconds.
Catalyst Can Degrade Alzheimer's-Related Amyloid Peptide Under Near-Infrared LightNews
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Αβ) under near-infrared (NIR) light irradiation has been developed.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018